Clinical Trial

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 \[HER2\]-negative) breast cancer.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-12-24; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2022-12-20
Trial Details
NCT Number NCT05187832
Lead Sponsor Kind Pharmaceuticals LLC
Conditions Advanced or Metastatic Breast Cancer
Enrollment 61 participants
Start Date 2022-10-05
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-27